No Data
No Data
Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $20
Citi Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $19
Intellia Therapeutics Is Maintained at Neutral by Goldman Sachs
Intellia Therapeutics Price Target Lowered to $19 From $25 at Citi
Intellia Therapeutics' NTLA-2002: Hold Rating Amid Competitive Challenges and Safety Concerns
Intellia Therapeutics: Promising Phase 2 Results and Growth Potential Justify Buy Rating
三和巴菲特 : Have you cried today? Baby
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 :
YWCYAPWEICHOY 叶伟财 OP 三和巴菲特 : Laughed.
71179109 : Intellia - 20% yesterday